We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Silica Microparticles Effectively Transport Anticancer Antibodies

By LabMedica International staff writers
Posted on 01 Jun 2010
Microparticles of porous silica (functionalized mesoporous silica, or FMS) have been used to transport effectively anticancer antibodies that slowed the growth of melanoma tumors in a mouse model.

Investigators at the University of Washington (Seattle, USA) loaded chemically modified silica microparticles to a very high density with antibodies specific to the CTLA4 cell surface protein, which is present on many types of cancer cells including melanoma. More...
The particles were approximately 6 µm to 12 µm in diameter and contained pores of about 30 nm in diameter. The pores were loaded to a super high density of about 0.4 mg − 0.8 mg of antibody per mg of FMS. Chemical modification of the FMS particles guaranteed long-lasting local release of the antibodies at the site of injection.

Results published in the May 3, 2010, online edition of the Journal of the American Chemical Society (JACS) revealed that FMS-anti-CTLA4 antibody injected directly into a mouse melanoma induced much greater and extended inhibition of tumor growth than did the antibody when given systemically or after having been injected into the tumor without microparticle carriers. Microparticle treatment prolonged the lives mice with melanoma. Of five mice that had been treated with particles alone (no antibody), all died within 21 days after treatment. In contrast, of the five mice treated with FMS-antibodies, three survived 21 days, and two were still alive at 34 days, when the experiment ended.

"We want to understand the mechanism, because not much is known about how the slowly leaked antibodies induce changes in the immune system or in the microenvironment of the tumor," said senior author Dr. Karl Erik Hellstrom, professor of pathology at the University of Washington.

Related Links:
University of Washington



New
Gold Member
Aspiration System
VACUSAFE
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The method that profiles DNA methylation in cell-free DNA from a single blood sample to detect disease signals system-wide (photo courtesy of Shutterstock)

cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample

Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read more

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.